Skip to content
  • Home
  • About us
  • Clinical trials
  • Blog
  • Contact us
  • Home
  • About us
  • Clinical trials
  • Blog
  • Contact us
Get started
icon
icon

icon
icon
icon Medical trials / View details
cancle-icon

TACTIVE-U: A Study to Learn About the Study Medicine (Called ARV-471) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)

Contact information

icon Pfizer CT.gov Call Center

icon Siteman Cancer Center - WUPI

icon Shiloh, illinois, Uniter States

Basic information

icon

icon Age

icon 35 Enrollment

icon
Breast Cancer Cancer
Trial Details
Brief Summary

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called ARV-471) when given together with other medicines for the potential treatment of advanced or metastatic breast cancer. This study is seeking participants who have breast cancer that: is advanced, may have spread to other organs (metastatic) and cannot be fully treated by surgery or radiation therapy is sensitive to hormonal therapy (it is called estrogen receptor positive); and is no longer responding to previous treatments This study is divided into separate sub-studies. For Sub-Study B: All participants will receive ARV-471 and a medicine called ribociclib. ARV-471 and ribociclib will be given at the same time by mouth, at home, 1 time a day. The experiences of people receiving the study medicine will be examined. This will help determine if the study medicine is safe and effective. Participants will continue to take ARV-471 and ribociclib until their cancer is no longer responding, or side effects become too severe. They will have visits at the study clinic about every 4 weeks.

Official Title

TACTIVE-U: AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B/2, OPEN-LABEL UMBRELLA STUDY TO INVESTIGATE TOLERABILITY, PK, AND ANTITUMOR ACTIVITY OF ARV-471 (PF-07850327), AN ORAL PROTEOLYSIS TARGETING CHIMERA, IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS AGED 18 YEARS AND OVER WITH ER+ ADVANCED OR METASTATIC BREAST CANCER, SUB-STUDY B (ARV-471 IN COMBINATION WITH RIBOCICLIB)

Selection Criteria
Eligibility Inclusion Criteria
    histological or cytological diagnosis of ER+ and HER2- advanced/metastatic breast cancer that is not amendable to surgical resection with curative intent (≥1% ER+ stained cells on the most recent tumor biopsy).
    prior anticancer therapies: up to 2 lines of prior therapies for advanced/metastatic disease; 1 line of any CDK4/6 inhibitor-based regimen is required (in any setting eg adjuvant, metastatic)
    at least 1 measurable lesion as defined by RECIST v1.1.
    ECOG PS ≤1.
Eligibility Exclusion Criteria
    visceral crisis at risk of life-threatening complications in the short term
    known history of drug-induced pneumonitis or other significant symptomatic deterioration of lung functions.
    newly diagnosed brain metastases, or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease. Participants with a history of CNS metastases or cord compression are eligible if they have been definitively treated, clinically stable and discontinued anti-seizure medications and corticosteroids for at least 14 days prior to enrollment in the of study.
    history of any other tumor malignancies within the past 3 years, except for the following: (1) adequately treated basal or squamous cell carcinoma of the skin; (2) curatively treated in situ carcinoma of the cervix.
    inflammatory breast cancer
    impaired cardiovascular function or clinically significant cardiovascular diseases
    concurrent administration of medications, food, or herb supplements that are strong inhibitors and strong/moderate inducers of CYP3A and drugs known to predispose to Torsade de Pointes or QT interval prolongation.
    renal impairment, not adequate liver function and/or bone marrow function
    known active infection

Join us! Be part of the smart work revolution.

Explore articles with tips and insights to know your about clinical matching

Contact us
Navigation
  • Home
  • About us
  • Clinical trials
  • Blog
  • Home
  • About us
  • Clinical trials
  • Blog
Address

L1N6Y1 / 26

Winston Crescent

Whitby, ON

Canada

Legal
  • Terms of use
  • Privacy Policy
  • Contact us
  • Terms of use
  • Privacy Policy
  • Contact us
Contact
+1 587-664-4986 info@horizonnt.ca
Get in touch
Horizon trial
  • Home
  • About us
  • Clinical trials
  • Blog
  • Contact us
  • Home
  • About us
  • Clinical trials
  • Blog
  • Contact us
Get started